<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04591938</url>
  </required_header>
  <id_info>
    <org_study_id>ENCORE-I</org_study_id>
    <nct_id>NCT04591938</nct_id>
  </id_info>
  <brief_title>FANTOM ENCORE Sirolimus-eluting Bioresorbable Scaffold for Treatment of De-novo CAD: the ENCORE-I Study</brief_title>
  <official_title>Safety and Efficacy of the FANTOM ENCORE Sirolimus-eluting Bioresorbable Scaffold for Treatment of De-novo Coronary Artery Disease: the ENCORE-I Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joost Daemen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Horizon 2020 - European Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>REVA Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multicentre, non-randomized, investigator-initiated study aiming to assess the&#xD;
      safety and efficacy of the Fantom Encore sirolimus-eluting bioresorbable scaffold (BRS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to 50 consecutive participants with de-novo non-complex obstructive coronary lesions and&#xD;
      non-ST elevation acute coronay syndromes or stable angina pectoris will be included in the&#xD;
      Netherlands and Belgium.&#xD;
&#xD;
      Device performance and behaviour will be assessed by angiography and optical coherence&#xD;
      tomography at the index procedure and at 13 months follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective, multicentre, non-randomized, investigator-initiated study</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Device-Oriented Composite Endpoint (DOCE)</measure>
    <time_frame>12 months</time_frame>
    <description>A composite of cardiac death, target vessel-related non-fatal myocardial infarction (MI) and clinically-driven target lesion revascularization(CD-TLR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subcomponents of DOCE</measure>
    <time_frame>30 days, 6, 12, 24, 36, 48 and 60 months</time_frame>
    <description>Subcomponents of the Device-Oriented Composite Endpoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization (TVR)</measure>
    <time_frame>30 days, 6, 12, 24, 36, 48 and 60 months</time_frame>
    <description>Target vessel revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Definite or probable stent thrombosis (ST)</measure>
    <time_frame>30 days, 6, 12, 24, 36, 48 and 60 months</time_frame>
    <description>Stent thrombosis</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Angiographic outcomes at baseline</measure>
    <time_frame>0 days</time_frame>
    <description>Acute gain</description>
  </other_outcome>
  <other_outcome>
    <measure>Angiographic outcomes at baseline</measure>
    <time_frame>0 days</time_frame>
    <description>acute recoil</description>
  </other_outcome>
  <other_outcome>
    <measure>Angiographic outcomes at baseline</measure>
    <time_frame>0 days</time_frame>
    <description>Incidence of procedural complications (dissection &gt;B, perforation, vessel closure, slow flow or no-reflow, intra-procedure scaffold thrombosis)</description>
  </other_outcome>
  <other_outcome>
    <measure>Angiographic outcomes at follow-up</measure>
    <time_frame>13 months</time_frame>
    <description>In-device and in-segment late lumen loss (LLL)</description>
  </other_outcome>
  <other_outcome>
    <measure>Angiographic outcomes at follow-up</measure>
    <time_frame>13 months</time_frame>
    <description>In-device and in-segment binary restenosis rate</description>
  </other_outcome>
  <other_outcome>
    <measure>Device performance</measure>
    <time_frame>0 days</time_frame>
    <description>Device success</description>
  </other_outcome>
  <other_outcome>
    <measure>Device performance</measure>
    <time_frame>0 days</time_frame>
    <description>Procedural success</description>
  </other_outcome>
  <other_outcome>
    <measure>Optical coherence tomography outcomes at baseline</measure>
    <time_frame>0 days</time_frame>
    <description>Incomplete strut apposition (ISA)</description>
  </other_outcome>
  <other_outcome>
    <measure>Optical coherence tomography outcomes at baseline</measure>
    <time_frame>0 days</time_frame>
    <description>Scaffold expansion</description>
  </other_outcome>
  <other_outcome>
    <measure>Optical coherence tomography outcomes at baseline</measure>
    <time_frame>0 days</time_frame>
    <description>Scaffold eccentricity</description>
  </other_outcome>
  <other_outcome>
    <measure>Optical coherence tomography outcomes at baseline</measure>
    <time_frame>0 days</time_frame>
    <description>Scaffold symmetry index</description>
  </other_outcome>
  <other_outcome>
    <measure>Optical coherence tomography outcomes at baseline</measure>
    <time_frame>0 days</time_frame>
    <description>Edge dissection</description>
  </other_outcome>
  <other_outcome>
    <measure>Optical coherence tomography outcomes at baseline</measure>
    <time_frame>0 days</time_frame>
    <description>In-device and in-segment endothelial shear stress</description>
  </other_outcome>
  <other_outcome>
    <measure>Optical coherence tomography outcomes at follow-up</measure>
    <time_frame>13 months</time_frame>
    <description>Neointima thickness</description>
  </other_outcome>
  <other_outcome>
    <measure>Optical coherence tomography outcomes at follow-up</measure>
    <time_frame>13 months</time_frame>
    <description>Percentage of patent struts</description>
  </other_outcome>
  <other_outcome>
    <measure>Optical coherence tomography outcomes at follow-up</measure>
    <time_frame>13 months</time_frame>
    <description>Percentage of uncovered struts</description>
  </other_outcome>
  <other_outcome>
    <measure>Optical coherence tomography outcomes at follow-up</measure>
    <time_frame>13 months</time_frame>
    <description>Persistent ISA</description>
  </other_outcome>
  <other_outcome>
    <measure>Optical coherence tomography outcomes at follow-up</measure>
    <time_frame>13 months</time_frame>
    <description>Acquired ISA</description>
  </other_outcome>
  <other_outcome>
    <measure>Optical coherence tomography outcomes at follow-up</measure>
    <time_frame>13 months</time_frame>
    <description>Scaffold eccentricity index</description>
  </other_outcome>
  <other_outcome>
    <measure>Optical coherence tomography outcomes at follow-up</measure>
    <time_frame>13 months</time_frame>
    <description>Scaffold symmetry index</description>
  </other_outcome>
  <other_outcome>
    <measure>Optical coherence tomography outcomes at follow-up</measure>
    <time_frame>13 months</time_frame>
    <description>In-device and in-segment late lumen area loss</description>
  </other_outcome>
  <other_outcome>
    <measure>Optical coherence tomography outcomes at follow-up</measure>
    <time_frame>13 months</time_frame>
    <description>In-device and in-segment binary restenosis rate.</description>
  </other_outcome>
  <other_outcome>
    <measure>Optical coherence tomography outcomes at follow-up</measure>
    <time_frame>13 months</time_frame>
    <description>In-device and in-segment endothelial shear stress</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Percutaneous Coronary Intervention</condition>
  <condition>Myocardial Revascularization</condition>
  <condition>Tomography, Optical Coherence</condition>
  <arm_group>
    <arm_group_label>Single arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Fantom Encore Bioresorbable scaffold implantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Fantom Encore Bioresorbable scaffold implantation</intervention_name>
    <description>Fantom Encore Bioresorbable scaffold implantation</description>
    <arm_group_label>Single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
          -  Stable angina, unstable angina or documented silent ischemia (invasive or non-invasive&#xD;
             test) or non-ST segment elevation acute myocardial infarction.&#xD;
&#xD;
          -  De-novo non-complex coronary obstructive lesions (&gt;50% stenosis as assessed by&#xD;
             quantitative coronary analysis (QCA))&#xD;
&#xD;
          -  The patient is willing and able to comply with the specified follow-up evaluations.&#xD;
&#xD;
          -  Reference vessel diameter (RVD) ≥ 2.5 mm and ≤ 4.0 mm by QCA.&#xD;
&#xD;
          -  During pre-dilatation, the pre-dilatation balloon is uniformly expanded to the full&#xD;
             intended diameter.&#xD;
&#xD;
          -  Target segment suitable for OCT imaging&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Target vessel with a distal Thrombolysis In Myocardial Infarction (TIMI) flow 0 or 1.&#xD;
&#xD;
          -  Target lesion located within 5.0 mm of vessel origin.&#xD;
&#xD;
          -  Lesion type ACC/AHA C.&#xD;
&#xD;
          -  Heavily calcified lesion&#xD;
&#xD;
          -  Severe tortuosity&#xD;
&#xD;
          -  Target lesion is located in or supplied by an arterial or venous bypass graft.&#xD;
&#xD;
          -  Target lesion requires treatment with a device other than the pre-dilatation balloon&#xD;
             prior to scaffold placement (including but not limited to directional coronary&#xD;
             atherectomy, excimer laser, rotational atherectomy, etc.).&#xD;
&#xD;
          -  Unsuccessful pre-dilatation, defined as a residual diameter stenosis ≥ 30%, assessed&#xD;
             by QCA.&#xD;
&#xD;
          -  Planned future revascularization of non-culprit lesions.&#xD;
&#xD;
          -  Presence of another device (stent or scaffold) located within the same segment (5mm&#xD;
             from the target lesion borders).&#xD;
&#xD;
          -  Patient is currently participating in another study with an investigational device or&#xD;
             an investigational drug and has not completed the entire follow-up period.&#xD;
&#xD;
          -  Impaired renal function (eGFR &lt;30ml/min).&#xD;
&#xD;
          -  Patient has a contraindication for the use of double antiplatelet therapy for at least&#xD;
             12 months.&#xD;
&#xD;
          -  Pregnant or breastfeeding patients.&#xD;
&#xD;
          -  Patient has a known allergy to contrast medium, sirolimus, Tyrosine-derived&#xD;
             polycarbonate or other structurally related compounds.&#xD;
&#xD;
          -  Patient is receiving chronic oral or intravenous immunosuppressive therapy or has&#xD;
             known life-limiting immunosuppressive or autoimmune disease (diabetes mellitus is not&#xD;
             an exclusion criteria).&#xD;
&#xD;
          -  Patient has a co-morbidity, which reduces life expectancy to ≤ 24 months, or&#xD;
             social-economic factors making compliance with the study requirements difficult.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joost Daemen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joost Daemen, MD, PhD</last_name>
    <phone>+31 10 703 5260</phone>
    <email>j.daemen@erasmusmc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ziekenhuis Oost-Limburg</name>
      <address>
        <city>Genk</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jo Dens, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tom Adriaenssens, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joost Daemen, MD;PhD</last_name>
      <phone>Tel: +31 10 703 5260</phone>
      <email>j.daemen@erasmusmc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Maria Natalia Tovar Forero, MD</last_name>
      <phone>Tel: +31 10 703 8896</phone>
      <email>m.tovarforero@erasmusmc.nl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 6, 2020</study_first_submitted>
  <study_first_submitted_qc>October 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>October 12, 2020</last_update_submitted>
  <last_update_submitted_qc>October 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>Joost Daemen</investigator_full_name>
    <investigator_title>Interventional Cardiologist</investigator_title>
  </responsible_party>
  <keyword>Bioresorbable scaffold</keyword>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <keyword>OCT</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

